Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study

Bingtian Dong, Ruiling He, Shenghong Ju, Yuping Chen, Ivica Grgurevic, Jianzhong Ma, Ying Guo, Huizhen Fan, Qiang Yan, Chuan Liu, Huixiong Xu, Anita Madir, Kristian Podrug, Jia Wang, Linxue Qian, Zhengzi Geng, Shanghao Liu, Tao Ren, Guo Zhang, Kun Wang, Meiqin Su, Fei Chen, Sumei Ma, Liting Zhang, Zhaowei Tong, Yonghe Zhou, Xin Li, Fanbin He, Hui Huan, Wenjuan Wang, Yunxiao Liang, Juan Tang, Fang Ai, Tingyu Wang, Liyun Zheng, Zhongwei Zhao, Jiansong Ji, Wei Liu, Jiaojiao Xu, Bo Liu, Xuemei Wang, Yao Zhang, Qiong Yan, Hui Liu, Xiaomei Chen, Shuhua Zhang, Yihua Wang, Yang Liu, Li Yin, Yanni Liu, Yanqing Huang, Li Bian, Ping An, Xin Zhang, Shaoting Zhang, Jinhua Shao, Xiangman Zhang, Wei Rao, Chaoxue Zhang, Christoph Frank Dietrich, Won Kim, Xiaolong Qi

Clin Mol Hepatol. 2025;31(3):881-898. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2024.0898

View: 2662 Download: 206

Correspondence

Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”

Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi

Clin Mol Hepatol. 2025;31(2):e155-e157. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0723

View: 1292 Download: 50

Letter to the Editor

Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”

Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li

Clin Mol Hepatol. 2025;31(2):e145-e148. Published online October 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0921

View: 1505 Download: 81

Original Article

Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Federico Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi

Clin Mol Hepatol. 2025;31(1):105-118. Published online July 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0198

View: 3888 Download: 334 Web of Science: 4 Crossref: 2

Correspondence

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”

Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani

Clin Mol Hepatol. 2023;29(1):188-190. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0408

View: 4306 Download: 74 Web of Science: 2 Crossref: 3

Editorial

A non-invasive risk stratification tool for hepatitis B-related liver cirrhosis: the Baveno VI-SSM combined model.

Ruiling He, Bingtian Dong, Xiaolong Qi

Received March 11, 2025 Accepted March 15, 2025

DOI: https://doi.org/10.3350/cmh.2025.0281 [Accepted]

View: 530 Download: 37

1 |

Viewed By 12525	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7624	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7105	MAFLD: How is it different from NAFLD?
Viewed By 5677	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5562	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 354	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search